Skip main navigation (Press Enter).

Hepatitis B Targeted in FDA’s Latest Disease-Specific Drug Advice

Share:

November 6, 2018

Treatment for chronic hepatitis B is getting a renewed focus from the Food and Drug Administration (FDA) thanks to newly released disease-specific industry advice on how to develop drugs for the disease.

Related Stories

Get Involved! Volunteer for the New Regulatory Response Subcommittee

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Raw Material Variability and Classification – Thinking beyond the Regulatory Submission

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments September 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments August 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

Regulatory Developments June 2023

Posted By Matt Baughman
Found In Microsite: AAPS Newsmagazine

«
1
2
3
4
5
...
»

Contact Us:

Kristen Kalmann, Content Manager
2107 Wilson Blvd. Ste. 200
Arlington, VA 22201

Advertising

View the Media Kit

AAPS Customer Service

1-703-243-2800

Copyright © 2024 AAPS Newsmagazine. All rights reserved.

Powered by Higher Logic

Global message icon